No products in the cart.
Cat:GMP-h-CNP
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Genemedi produces core diagnostic ingredients for test of Cardiovascular disease (cardiovascular disease) and related syndrome. GeneMedi offers paired diagnostics grade C-type natriuretic peptide (CNP) antibodies (monoclonal antibody, mab) and antigens for Cardiovascular disease (cardiovascular disease) rapid test kit of C-type natriuretic peptide (CNP) testing in standard substance, positive control, ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT. All the antibodies and antigens for Cardiovascular disease (cardiovascular disease ) test are suitable for in functional ELISA, and other immunoassays in dignostics.The antibodies can act as a capture antibody and detection antibody. The antigens can be used as positive control.The natriuretic peptide
system comprises three structurally related peptides: atrial natriuretic
peptide, B-type natriuretic peptide and C-type natriuretic peptide. In
circulation, they play an important endocrine role in the regulation of
cardiovascular homeostasis by maintaining blood pressure and extracellular
fluid volume. Atrial natriuretic peptide, B-type natriuretic peptide and C-type
natriuretic peptide have gained considerable diagnostic interest as biomarkers
in cardiovascular disease.
Product Description
Cat No. of Pruducts
GMP-h-CNP-Ag01:Recombinant Human CNP Protein
Product Name
Recombinant Human CNP Protein
Target
C-type natriuretic peptide
Alias of Target/Biomarker
CNP1, HLD20
Expression platform
E.coli
Isotypes
Recombinant Antigen
Bioactivity validation
C-type natriuretic peptide (CNP) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in CNP level test of Cardiovascular disease (cardiovascular disease) and related syndrome evaluation
Tag
His
Products description
Recombinant Human CNP Protein was expressed in E.coli -based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.
Reconized/Reactive Species
Human
Purity
Purity: ≥95% (SDS-PAGE)
Application
Standard substance, positive control, ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA),immunonephelometry and POCT.
Formulation
Supplied as a 0.2 μM filtered solution of PBS,PH7.4.
Storage
Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.
Previous slide
Next slide
Cat No. of Pruducts
GMP-h-CNP-Ab01,GMP-h-CNP-Ab02:Anti-Human CNP mouse monoclonal antibody (mAb)
Product Name
Anti-Human CNP mouse monoclonal antibody (mAb)
Target
Alias of Target/Biomarker
CNP1, HLD20
Expression platform
Hybridoma
Isotypes
Mouse IgG
Bioactivity validation
Human C-type natriuretic peptide (CNP) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other C-type natriuretic peptide (CNP) antibodies in CNP level test of Cardiovascular disease (cardiovascular disease) and related syndrome evaluation.
Tag
mFc
Products description
Anti-Human CNP mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by hybridoma technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other C-type natriuretic peptide (CNP) antibodies.
Reconized/Reactive Species
Human
Purity
Purity: ≥95% (SDS-PAGE)
Application
ELISA test, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT
Formulation
Supplied as a 0.2 μM filtered solution of PBS,PH7.4.
Storage
Store at? -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.
Diagnostic antibodies and antigens for cancer detection - TG, CA-125, SCC Ag, PIVKA-Ⅱ, ProGRP, Calcitonin, NSE, CA-724, HE4, CA15-3, FER, CYFRA21-1, HER2, HSP90α, S100B, CEA, AFP, sFlt-1, PSA, hEGF, TFF2, TFF3, CA199, CA50, TK1
Regardless of the advances in the cancer therapy, delayed symptoms and lack of successful diagnosis of cancer at early stage increased the death rate. Tumor-associated antigens (TAAs) and their antibodies have been identified as potential markers in cancer diagnosis and determination. TAAs and their antibodies-based detection of cancer have the advantages such as low-cost, and simple access, which attracted much attention for early cancer detection. For several reasons, tumor marker itself is typically insufficient to analyze disease conditions. Because, maximum number of markers have been produced by both normal and cancer cells. Several cancers such as anal, breast, ovaries, testicles, colon, endometrial, peritoneal, fallopian tube, gallbladder, gastric, liver, lung, neuroendocrine, pancreatic, prostate, renal, cervix, stomach and thyroid cancer, bronchopulmonary dysplasia, hepatitis, hematological malignancies, hemochromatosis, hypercalcemia, osteoporosis, Parget’s diseases and so on have been identified using specific marker. Detecting the quantity of marker proteins from different samples may benefit from ELISA, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT.
